Drug Trial Radar · NCT04691804
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
496
Actual
Start
Mar 18, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Fuzuloparib , Abiraterone acetate and PrednisoneDrug
1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po 2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po 3. Prednisone tablets (strength: 5 mg) 5mg, Bid po
Fuzuloparib Placebo, Abiraterone acetate and PrednisoneDrug
1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po 2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po 3. Prednisone tablets (strength: 5 mg)5mg, Bid po
Primary outcomes
What the sponsor says the trial is designed to measure.
- rPFS by blinded independent central review (BICR) using RESIST1.1 and PCWG3Time frame: up to 3 years
Locations
147 sites in 13 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Urological Associates of Southern Arizona PC
Tucson, Arizona
Desert Hematology Oncology Medical Group Inc
Rancho Mirage, California
San Bernardino Urological Associates Medical Group
San Bernardino, California
UF College of Medicine - Jacksonville
Jacksonville, Florida
Hematology Oncology Clinic
Baton Rouge, Louisiana
VA Maryland Health Care System
Baltimore, Maryland
Johns Hopkins
Baltimore, Maryland
Henry Ford Health System
Detroit, Michigan
GU Research Network LLC
Omaha, Nebraska
John Theurer Cancer Center
Hackensack, New Jersey
Weill Cornell Medicine
New York, New York
Messino Cancer Centers
Asheville, North Carolina
Gabrail Cancer Center Research
Canton, Ohio
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina
Tennessee Oncology
Chattanooga, Tennessee
Center for Onology and Blood Disorders
Houston, Texas
Bendigo Health
Bendigo, Australia
Concord Repatriation General Hospital
Concord, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Gosford Hospital
Gosford, Australia
Ashford Cancer Centre Research
Kurralta Park, Australia
The Alfred Hospital
Melbourne, Australia
Western Health
St Albans, Australia
Macquarie University
Sydney, Australia
Riverina Cancer Care Centre
Wagga Wagga, Australia
Sydney Adventist Hospital
Wahroonga, Australia
UZ Gent
Ghent, Belgium
Centre Hospitalier de Jolimont
Haine-Saint-Paul, Belgium
AZ Groeninge
Kortrijk, Belgium
Beijing cancer hospital
Beijing, China
Beijing Friendship Hospital
Beijing, China
Beijing Hospital
Beijing, China
Cancer hospital Chinese academy of medical science
Beijing, China
Hunan Cancer Hospital
Changsha, China
XiangYa hospital central south university
Changsha, China
Sichuan Provincial People's Hospital
Chengdu, China
West China Hospital of Sichuan University
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.